Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble(Cedars-Sinai Medical Center), Talmadge E. King(University of California, San Francisco), Ian Glaspole(Monash University), Carlo Albera(University of Turin), David J. Lederer(Regeneron (United States)), Steven D. Nathan(Inova Fairfax Hospital), Dominique Valeyre(Inserm), Williamson Z. Bradford(InterScience (United States)), Marilyn K. Glassberg(University of Miami), Ulrich Costabel(Ruhrlandklinik), Jonathan A. Leff, Carlos A. Pereira(Universidade Federal de São Paulo), Robert Fishman, Elizabeth A. Fagan, Jeffrey J. Swigris(National Jewish Health), Roland M. du Bois(Imperial College London), Lisa Lancaster(Vanderbilt University Medical Center)
Cited by 462
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
|Immunity|2009|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k